The company offers highly pure and genetically uniform cardiomyocytes, as well as endothelial and smooth muscle cells, for use in toxicity testing, drug development, and other cell-based test models. Axiogenesis also provides culture media and can perform in-house tests for clients. Their technologies greatly improve the speed and confidence in discovering new therapies, and reduce attrition of failed compounds. Axiogenesis offers licensing of proprietary disease models for compound screening and value-added fee-for-service assays for in vitro toxicology, safety pharmacology, and drug discovery.